大小单双APP(正规好玩)官方网站

en-us/category/$id.htm

Research and Development R & D

Ina-cel Pipeline Publications

Time：2024/12/07 Source：Blood - 2024 ASH Annual Meeting Abstract

Development of a Novel Allogeneic Super-γδ T Cell Therapy for Acute Myeloid Leukemia and Multiple Tumors
Time：2024/12/05 Source：Blood - 2024 ASH Annual Meeting Abstract

Efficacy and Safety of Inaticabtagene Autoleucel in Children with Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukemia in China
Time：2024/12/03 Source：Blood Advances

Inaticabtagene Autoleucel (CNCT19) in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Time：2024/11/05 Source：Blood - 2024 ASH Annual Meeting Abstract

CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
Time：2024/11/05 Source：Blood - 2024 ASH Annual Meeting Abstract

Development of Allogeneic Dual-Targeting CD19/BCMA CAR-T Cell Therapeutics Using ALL-in-One Site-Specific Integration Technology for Autoimmune Diseases
Time：2024/11/05 Source：Blood - 2024 ASH Annual Meeting Abstract

Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: An Updated Report on the Pivotal Study of Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-Cell ALL) in China

1 2 3 4

我们的目标 Focus on Cell Therapy, Lead a Healthy Future.